Analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will post earnings of ($1.15) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($1.14). Theravance Biopharma reported earnings of ($1.36) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.4%. The firm is scheduled to issue its next quarterly earnings report on Monday, February 26th.
On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.84) per share for the current financial year, with EPS estimates ranging from ($5.01) to ($4.49). For the next fiscal year, analysts expect that the company will post earnings of ($4.44) per share, with EPS estimates ranging from ($4.75) to ($4.17). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.05). Theravance Biopharma had a negative return on equity of 99.43% and a negative net margin of 1,604.87%.
Theravance Biopharma (TBPH) traded up $0.31 during midday trading on Friday, reaching $28.32. 200,344 shares of the company’s stock traded hands, compared to its average volume of 116,199. Theravance Biopharma has a fifty-two week low of $23.15 and a fifty-two week high of $43.44. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21. The stock has a market cap of $1,532.20, a PE ratio of -5.48 and a beta of 2.10.
Several large investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. increased its holdings in shares of Theravance Biopharma by 4.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 199,677 shares of the biopharmaceutical company’s stock worth $5,569,000 after buying an additional 8,119 shares during the last quarter. Moneta Group Investment Advisors LLC bought a new position in shares of Theravance Biopharma in the 3rd quarter worth $299,000. Wells Fargo & Company MN increased its holdings in shares of Theravance Biopharma by 32.0% in the 3rd quarter. Wells Fargo & Company MN now owns 117,079 shares of the biopharmaceutical company’s stock worth $4,009,000 after buying an additional 28,391 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Theravance Biopharma by 15.7% in the 3rd quarter. Legal & General Group Plc now owns 18,840 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 2,551 shares during the last quarter. Finally, American International Group Inc. increased its holdings in shares of Theravance Biopharma by 8.1% in the 3rd quarter. American International Group Inc. now owns 28,000 shares of the biopharmaceutical company’s stock worth $959,000 after buying an additional 2,094 shares during the last quarter. 86.34% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/21/1-15-eps-expected-for-theravance-biopharma-inc-tbph-this-quarter.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.